Photetica Sets Sights on Preventing and Reversing the Side Effects of Chemotherapy in Breast Cancer Patients
Austin-based tech company, Photetica, is now in the clinical trial phase with its newest medical device, Lazarus, and has launched a crowdfunding campaign through Indiegogo to support clinical studies.
Austin, TX (PRWEB) April 28, 2014
Lazarus, the patented medical technology designed to prevent and reverse chemotherapy side effects during breast cancer treatment, today announced their global launch to secure funds for clinical trials through Indiegogo. Photetica has been working on researching and developing Lazarus for the past five years. The patented technology is in clinical studies at a Rochester, Minnesota based oncology research and treatment center. The crowdfunding campaign has been launched to support the clinical studies and put Lazarus in market by Q4 2015.
“The problem with treating breast cancer isn’t that the chemotherapy drugs aren’t effective, it’s that the side effects of the drugs are brutal and the collateral damage is often permanent. No one has successfully addressed the problem of chemotherapy side effects and the patients who are undergoing chemotherapy are desperate for this solution,” said Bradford Richdale, CEO and founder of Photetica.
Richdale formed Photetica in 2005 to acquire the patented intellectual property from former CEO and Chairman of Ford, the late Red Poling. Richdale discovered what the technology could do for chemotherapy patients when a friend was diagnosed with Stage III Lymphoma. “She had no feeling in her hands and feet, a condition known as chemotherapy induced peripheral neuropathy (CIPN) and her neutrophil (a type of white blood cell) count was too low to continue chemotherapy. The drugs designed to boost her neutrophil count didn’t work. After five treatments she restored the feeling in her hands and feet then resumed her treatment regimen successfully completing her treatment,” Richdale added.
CIPN is caused by the drugs that treat breast and other types of cancer. It’s one of the most common reasons that cancer patients stop chemotherapy due to the unrelenting chronic pain that it causes. Breast cancer patients are particularly susceptible to CIPN since the drugs proven to treat breast cancer according to http://www.cancernetwork.com cause CIPN IN 70-90 percent of breast cancer patients. According to the American Cancer Society 30-40 percent of all chemo patients get CIPN.
Photetica has spent the past five years modifying their intellectual property to focus on treating the side effects of chemotherapy. The side effects include CIPN, pain, sleeplessness, nausea and depression. Their low level laser based technology sends light into the hands and feet of breast cancer patients at such a low level that no radiation is emitted. This unique aspect of their technology led to the FDA issuing a non-significant risk classification when the company submitted their protocols to the FDA for approval, a prelude to the start of their clinical studies at a Rochester, Minnesota based oncology research and treatment center.
Photetica was founded by CEO Bradford Richdale. For over 30 years Bradford Richdale he’s been the founder, entrepreneurial principal, or served as a senior executive (primarily as the Chairman, CEO or Board Director level) of publicly-traded and private companies. He’s joined by CMO Hugo Hasselhuhn who also has over thirty years of design, management and on-time, on budget manufacturing of electronics products for both consumers and Fortune 500 corporate clients. Along with COO Skip Eavers' 25 year professional career that has been focused on transforming innovative research, technologies, products and services into well run, high-growth businesses.
For the original version on PRWeb visit: http://www.prweb.com/releases/photetica/breast-cancer-cipn/prweb11800860.htm